Cancer Genomics
Description
The Cancer Genomics group is also working on identifying somatic mutations involved in the mechanisms of sensitivity or resistance to PI3K inhibitors in breast cancers and gliomas. It is working in close collaboration with basic and clinical researchers from the genomics service in Vall d'Hebron Institute of Oncology.